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Because of the practical inconvenience of i.m. injections, patterns and pregnancy outcomes after in-vitro fertilization alternative routes for administering progesterone have been and intracytoplasmic sperm injection (IVF-ICSI). The sought. In micronized form, progesterone is absorbed when study population consisted of 149 consecutive women who given orally but is nearly completely metabolized (Ͼ90%) had undergone IVF-ICSI using 'long-protocol' stimulation during its first pass through the liver (Nahoul et al., 1993) .
with buserelin-human menopausal gonadotrophin (HMG).
This explains the previous observation that oral micronized A retrospective chart analysis of computerized medical progesterone (300 mg/day), administered in conjunction with records was undertaken. Vaginal progesterone (200 mg physiological amounts of oestradiol, failed to achieve the three times daily) was begun the day before oocyte retrieval predecidual transformation of the endometrial stroma and continued for a minimum of 16-19 days following (Bourgain et al., 1990) . In order to obtain the minimal human chorionic gonadotrophin (HCG) administration.
intratissular progesterone concentration to achieve transOccurrence of bleeding following HCG injection, formation of hyperstimulated endometrial tissue there would pregnancy rate and outcomes, and serum concentrations be a need for such a high oral dose that it would cause of oestradiol were measured. Women undergoing IVF and somnolence, sedation and hypnose (Arafat et al., 1988) . embryo transfer with ICSI and using vaginal progesterone Transdermal administration of progesterone is also not for luteal support had normal luteal phase lengths (day of feasible (Cooper et al., 1998) , as the skin is poorly permeable HCG minus day of onset of bleeding). In the absence of to the drug and rich in the enzyme 5-α-reductase, which will pregnancy, bleeding occurred after 19.2 ⍨ 3.9 days (mean inactivate the small amount of progesterone that is able to ⍨ SD). Out of the pregnant group only three women bled penetrate the skin. Hence, the vaginal route is the only within 19 days of HCG administration: two had biochemical remaining practical option for administration of progesterone pregnancies which spontaneously vanished and one evolved for luteal support-replacing the painful i.m. injections. to term. The results reflect the normal bleeding pattern to
In previous work, it has been shown that progesterone be expected when vaginal progesterone is used for luteal administered vaginally (200 mg three times daily) is capable support in IVF and embryo transfer, an approach whose of reproducing all the endometrial changes normally seen in efficacy has been amply proven. No shortened luteal phases the luteal phase of the menstrual cycle (Devroey et al., 1989 ; were observed using vaginally administered progesterone. Smitz et al., 1992 Smitz et al., , 1993 . Furthermore, vaginal progesterone Key words: assisted reproduction technology/bleeding/ supports nidation and development of pregnancy in women oestrogen/vaginal progesterone without ovarian function (Devroey et al., 1989) . Several authors, puzzled by the unusual efficacy of vaginal progesterone, have examined uterine tissue concentrations of progesterone and have gathered evidence that some degree of Introduction direct transport from the vagina to the uterus exists. Miles et al. (1994) observed higher endometrial concentrations of Luteal support is necessary in ovarian stimulation protocols, such as those commonly prescribed for in-vitro fertilization progesterone with vaginal administration, compared with the concentrations following i.m. injections (50 mg twice daily), (IVF) and embryo transfer (Smith et al., 1989; Belaisch-Allart et al., 1990 (day 0) and on days 16 and 19 (corresponding to days 12 and 15 after embryo transfer). A diagnosis of pregnancy was established using β-HCG values obtained on days 16 and 19 using the Tandem-
Materials and methods
HCG ® assay (Hybritech, Liège, Belgium) with 10 IU/l as the threshold value.
Study population
This study was designed to evaluate the effects of vaginal micronized Statistical methods progesterone on bleeding following HCG administration in IVF-ICSI Statistical analyses were performed with MedCalc TM software procedures.
(MedCalc Software, Mariakerke, Belgium). Variables (patient A retrospective analysis was conducted of the computerized medical characteristics and assisted reproduction treatment outcome data, records of 149 consecutive women who had undergone ICSI between mean hormone concentrations, and bleeding patterns) were evaluated January 1 and April 30, 1996. Women were eligible for review if using the χ 2 test, Student's test, and the Wilcoxon signed ranks test. they had completed a routine assisted reproduction-ICSI procedure Statistical significance was determined at P ഛ 0.05. [using 'long-protocol' stimulation with buserelin-human menopausal gonadotrophin (HMG) within the specified time period] and had received vaginal micronized progesterone for luteal phase
Results

supplementation without oestrogen or HCG supplements. No restric-
The mean age of the 149 women was 32 years (Table I) This sample of women had experienced from one to six previous assisted reproduction attempts (median: one). Fifty-
Collection of information on bleeding pattern
two of the 149 women (35%) became pregnant using this During the luteal phase all patients were systematically instructed to study protocol. No statistically significant differences were have routine contact by telephone with the nursing staff to enquire observed in these variables when comparing women who about their hormonal profile, to report on eventual side-effects and became pregnant with those who did not.
to state whether any abnormal vaginal bleeding had occurred. The data were recorded in writing from the telephone conversation directly Bleeding patterns, pregnancy outcomes and serum oestradiol onto the patients' individual charts kept in the laboratory and were concentrations then transferred to a computer operator to input. In the third week after oocyte retrieval, all patients were contacted by a senior scientist For women who did not become pregnant (n ϭ 97), to receive their instructions on eventual follow-up of pregnancy, and bleeding occurred after a mean of 19.2 Ϯ 3.9 days following in cases of no pregnancy, the first day of the menstrual bleeding was HCG administration (median: 18 days; range: 11-41 days). also notified.
Only one of the non-pregnant women experienced early menstruation; this occurred on the 11th day post-HCG. A total Treatment protocol of 65% of the non-pregnant women experienced bleeding Women whose charts were reviewed for this study had been allocated before vaginal progesterone treatment was discontinued.
to ICSI for two reasons: a partner with a low sperm count (defined There were 40 deliveries out of 52 pregnancies in the 149 following embryo transfer (i.e. 16 and 19 days after HCG administrawomen whose charts were reviewed for this study. On these tion). Vaginal micronized progesterone (200 mg three times daily in 40 deliveries, 65% were singletons, 27.5% were twins, and soft gelatin capsules; Piette Pharmaceuticals, Brussels, Belgium) was 7.5% were triplets. Of the remaining 12 women, three had begun on the day before oocyte retrieval and continued until the only biochemical evidence of pregnancy, one had an ectopic second β-HCG determination even if early bleeding was noted. If pregnancy, and eight women spontaneously aborted (seven β-HCG was positive, vaginal progesterone was maintained until week 10 of the pregnancy.
early and one late). the two groups, which indicated a similar response to ovarian stimulation in both groups. However, on both end-luteal control days mean oestradiol concentrations were significantly higher in pregnant women than in non-pregnant women (P Ͻ 0.0001).
Serum oestradiol concentrations were lower in women who 
Discussion
It has previously been shown that vaginal administration of Statistically significant differences (P ϭ 0.0001) were seen between pregnant and non-pregnant women with regard to progesterone (200 mg three times daily) was an effective way of priming endometrial receptivity and favouring the mean serum concentrations of oestradiol on day 19 following HCG administration (Figure 2) . On the day of HCG injection development of pregnancy in IVF and embryo transfer (Devroey et al., 1989; Bourgain et al., 1993) . In the present (day 0), mean serum oestradiol concentrations were similar in retrospective study of 149 women who used vaginal micronized reproduction treatment (e.g. ovarian stimulation and ovarian stimulation with IVF). The major drawback of the current progesterone as luteal phase support, the pregnancy rate per cycle (35%) and low fetal wastage observed confirmed regimens for luteal support with vaginal progesterone is the need for multiple (three) daily administrations (Devroey et al., earlier findings (Smitz et al., 1992a (Smitz et al., , 1993 . In addition, using a human ex-vivo perfusion model, Bulletti et al. (1997 Bulletti et al. ( ) 1989 Schmidt et al., 1989) . New options are emerging, however, with the development of a sustained-release gel of confirmed that a fraction of vaginally administered progesterone was transported directly to the uterus corpus. Hence, progesterone (Crinone 8% ® ; Wyeth-Ayerst Pharmaceuticals, Radnor, PA, USA), which removes the need for multiple these results further support the decision to use vaginal progesterone routinely for luteal support in IVF.
administrations (Fanchin et al., 1997) .
In conclusion, this study demonstrated that early bleeding The objective of this retrospective study was to evaluate the bleeding patterns in pregnant and non-pregnant IVF patients.
following administration of vaginal progesterone for luteal phase support occurred almost exclusively in women who had Hence, to ensure population homogeneity, it appeared reasonable to select women undergoing the same ovarian stimulation not become pregnant. treatment protocol. The 'long GnRHa' protocol with late luteal onset of GnRHa treatment was retained for the present study References because it is the standard treatment for IVF in this centre.
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